122 related articles for article (PubMed ID: 9839579)
1. Does voided urine cytology have biological significance?
Tut VM; Hildreth AJ; Kumar M; Mellon JK
Br J Urol; 1998 Nov; 82(5):655-9. PubMed ID: 9839579
[TBL] [Abstract][Full Text] [Related]
2. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
3. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
[TBL] [Abstract][Full Text] [Related]
4. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
Leyh H; Mazeman E
Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
[TBL] [Abstract][Full Text] [Related]
5. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
Schamhart DH; de Reijke TM; van der Poel HG; Witjes JA; de Boer EC; Kurth K; Schalken JA
Eur Urol; 1998 Aug; 34(2):99-106. PubMed ID: 9693243
[TBL] [Abstract][Full Text] [Related]
6. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
7. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
Heino A; Aaltomaa S; Ala-Opas M
Ann Chir Gynaecol; 1999; 88(4):304-7. PubMed ID: 10661829
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
[TBL] [Abstract][Full Text] [Related]
9. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.
Smrkolj T; Cegovnik Primozic U; Fabjan T; Sterpin S; Osredkar J
Radiol Oncol; 2020 Dec; 55(2):196-202. PubMed ID: 33764701
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression.
Zieger K; Wolf H; Olsen PR; Hojgaard K
BJU Int; 2000 May; 85(7):824-8. PubMed ID: 10792160
[TBL] [Abstract][Full Text] [Related]
11. Can sensitivity of voided urinary cytology or bladder wash cytology be improved by the use of different urinary portions?
Mungan NA; Kulacoglu S; Basar M; Sahin M; Witjes JA
Urol Int; 1999; 62(4):209-12. PubMed ID: 10567884
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
[TBL] [Abstract][Full Text] [Related]
13. The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder.
Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS
Br J Urol; 1996 Aug; 78(2):209-12. PubMed ID: 8813915
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
Konety BR; Metro MJ; Melham MF; Salup RR
Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
[TBL] [Abstract][Full Text] [Related]
16. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
[TBL] [Abstract][Full Text] [Related]
18. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Gupta NP; Sharma N; Kumar R
Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
[TBL] [Abstract][Full Text] [Related]
19. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]